Home


Login
November 20, 2008
A new path to hope

Brainsgate is a medical device company committed to developing a novel treatment modality, electrical SPG stimulation. This platform technology has been shown to increase blood flow to the brain and as a result has broad potential for treating central nervous system disorders. BrainsGate is currently focusing on:

1. Improve the outcome of patients suffering from ischemic stroke, in a 24 hour window after onset of symptoms.

2. Enable drug delivery into the central nervous system, overcoming the blood-brain barrier, and opening a window for addressing currently untreatable CNS diseases.


Focus: Stroke
The leading cause of adult long-term disability and the third leading cause of death read more
Focus: the spheno-palatine ganglion
Two small nervous centers located above the roof of the mouth near the sinuses read more
September 25, 2008
BrainsGate launches ImPACT-24
ImPACT-24 is a randomized, sham-controlled, double blind study to test the safety and efficacy of BrainsGate's ISS for treatment of acute ischemic stroke victims in a 24 hour window > full story
August 13, 2008
BrainsGate raises $27.5m
This is the first investment in Israel in over a year by Johnson & Johnson's VC arm. by Gali Weinreb > full story